MoonLake Immunotherapeutics MLTX Insider Ownership

NASDAQ MLTX

$10.60 +0.28 (+2.71%)

As of: Oct 21, 2026 · 11:41 AM EDT

Insider Holdings by Owner

13.02Mn Shares

Insider Ownership Statistics

as of 30 Sep, 2026

Insider Ownership

13.32%

▼-0.356% pp QoQ

Shares Held by Insiders

9.84Mn

filed for Sep 2026

▼-2.61% QoQ

Shares Outstanding

73.92Mn

73,915,296 shares

Direct Holdings

5.14Mn

Indirect: 4.71Mn

Net Shares Traded (QoQ)

-263.35K

net selling in Sep 2026

Insiders Holding Shares

with Form 4 holdings on file

Shares Owned by Insiders

Shares held % of outstanding

Latest —

Average ownership —

Peak ownership —

Shares Purchased/Sold by Insiders

Bought Sold

Latest quarter —

Net over range —

Buying quarters —

Insider Ownership Summary

Updated Oct 10, 2026

Over the past year, MLTX insiders sold $81.07 million of stock (4.75Mn shares) on the open market and bought none.

A count shows 4 insiders selling MLTX stock on the open market over the past 12 months and none buying.
BVF Partners L.P. (Director and 10% owner) led open-market sales of MoonLake Immunotherapeutics stock over the past 12 months with $62.96 million (3.75Mn shares), most recently on March 31, 2026.
MoonLake Immunotherapeutics' latest insider trade on the open market was a sale of 1.1K shares for $22,000 by Kristian Reich (Chief Scientific Officer) on July 27, 2026.
Apart from open-market trades, MLTX insiders received 354.3K shares in stock awards and acquired 526.18K shares through option exercises and conversions in the past 12 months.
Per Business Quant data, MoonLake Immunotherapeutics insiders hold 9.84Mn shares in total based on their latest Form 4 filings, down 2.61% from 10.11Mn shares at the end of Q2 2026 and down 9.49% from 10.87Mn shares at the end of Q3 2025.
Indirect holdings, through trusts, partnerships, family members and other entities, make up 47.81% (4.71Mn shares) of MoonLake Immunotherapeutics' insider total, with the other 52.19% (5.14Mn shares) held directly.
Holdings in MoonLake Immunotherapeutics stock are reported by 6 insiders, the officers, directors and 10% owners who have filed a Form 4 in the past two years.
MoonLake Immunotherapeutics' three biggest insider holders are Da Silva Jorge Santos (Chief Executive Officer, 2.77Mn shares), Kristian Reich (Chief Scientific Officer, 2.75Mn shares) and Bihua Chen (1.99Mn shares), based on their latest Form 4 filings.
The holding of Da Silva Jorge Santos makes up 28.19% of all shares held by MoonLake Immunotherapeutics insiders.
Institutions held 99.08% of MoonLake Immunotherapeutics' outstanding shares in their Q2 2026 13F filings.
Over the past 12 months, 8 insiders reported transactions in MoonLake Immunotherapeutics stock in 27 Form 4 filings.
This summary of MoonLake Immunotherapeutics insider activity covers Form 4 filings through July 29, 2026.

Form 4 Holdings

Insiders Holding MLTX

Insiders 7

Shares held 13.02Mn

Of outstanding 17.62%

#	Insider	Position	Direct	Indirect	Total	Share of Insiders	Last Filed
1	Holdings Llc Helix	Other	3,215,000	0	3,215,000	24.7%	07 Apr, 2022
2	Da Silva Jorge Santos	Chief Executive Officer	2,774,893	0	2,774,893	21.3%	13 Jul, 2026
3	Kristian Reich	Chief Scientific Officer	0	2,711,198	2,711,198	20.8%	29 Jul, 2026
4	Bihua Chen	Ceo And Chairman	0	1,994,173	1,994,173	15.3%	01 Oct, 2025
5	Matthias Bodenstedt	Chief Financial Officer	1,115,435	0	1,115,435	8.6%	23 Jun, 2026
6	Partners L P/Il Bvf	Director, TenPercentOwner	1,039,238	0	1,039,238	8.0%	02 Apr, 2026
7	Simon Sturge	Director	171,980	0	171,980	1.3%	08 Oct, 2024

Each row is that insider’s most recently reported position, from Form 4 filings over the last 60 months — which is why this total does not tie to the quarterly series above, where a quarter counts only the insiders who filed in it. Shares held through a fund or institutional portfolio are counted on the institutional ownership page instead.

Form 4 Filings

184 Insider Transactions

Source SEC Form 4

Latest quarter Sep 2026

Date	Insider	Position	Transaction	Shares	Price	Value	Shares Held After	Ownership
27 Jul, 2026	Kristian Reich	Chief Scientific Officer	Disposed S	1,100	$20.00	$22.00K	2,711,198	Indirect
21 Jul, 2026	Kristian Reich	Chief Scientific Officer	Disposed S	50,000	$20.02	$1.00Mn	2,714,746	Indirect
22 Jul, 2026	Kristian Reich	Chief Scientific Officer	Disposed S	2,448	$20.00	$48.96K	2,712,298	Indirect
20 Jul, 2026	Kristian Reich	Chief Scientific Officer	Disposed S	43,700	$20.09	$877.93K	2,764,746	Indirect
15 Jul, 2026	Kristian Reich	Chief Scientific Officer	Disposed S	16,105	$20.01	$322.26K	2,808,446	Indirect
09 Jul, 2026	Da Silva Jorge Santos	Chief Executive Officer	Disposed S	33,936	$20.01	$679.06K	2,843,182	Direct
10 Jul, 2026	Da Silva Jorge Santos	Chief Executive Officer	Disposed S	68,289	$20.02	$1.37Mn	2,774,893	Direct
01 Jul, 2026	Da Silva Jorge Santos	Chief Executive Officer	Disposed S	47,775	$20.03	$956.93K	2,877,118	Direct
22 Jun, 2026	Matthias Bodenstedt	Chief Financial Officer	Disposed S	39,120	$22.04	$862.20K	1,115,435	Direct
17 Jun, 2026	Partners L P/Il Bvf	Director, TenPercentOwner	Acquired A	22,195	$0.00	$0	22,195	Indirect
17 Jun, 2026	Matthias Bodenstedt	Chief Financial Officer	Disposed S	15,082	$19.68	$296.81K	1,157,349	Direct
17 Jun, 2026	Spike Loy	Director	Acquired A	22,195	$0.00	$0	22,195	Direct
17 Jun, 2026	Ramnik Xavier	Director	Acquired A	22,195	$0.00	$0	22,195	Direct
17 Jun, 2026	Andrew John Phillips	Director	Acquired A	22,195	$0.00	$0	22,195	Direct
17 Jun, 2026	Catherine Moukheibir	Director	Acquired A	22,195	$0.00	$0	22,195	Direct
18 Jun, 2026	Matthias Bodenstedt	Chief Financial Officer	Disposed S	2,794	$19.60	$54.76K	1,154,555	Direct
15 Jun, 2026	Kristian Reich	Chief Scientific Officer	Disposed S	50,000	$18.89	$944.50K	2,924,551	Indirect
16 Jun, 2026	Kristian Reich	Chief Scientific Officer	Disposed S	50,000	$18.70	$935.00K	2,874,551	Indirect
17 Jun, 2026	Kristian Reich	Chief Scientific Officer	Disposed S	50,000	$19.43	$971.50K	2,824,551	Indirect
11 May, 2026	Matthias Bodenstedt	Chief Financial Officer	Disposed S	13,653	$20.02	$273.33K	1,172,431	Direct

Showing 1 to 20 of 184 transactions